Ratings Nihon Kohden Corporation

Equities

6849

JP3706800004

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-06-06 am EDT			5-day change	1st Jan Change
4,761 ^JPY	-1.53%		+2.34%	+6.68%

May. 13	Nihon Kohden Corporation Announces Dividend for the Fiscal Year Ended March 31, 2024	CI
May. 13	Nihon Kohden Corporation Provides Dividend Guidance for the Interim Second Quarter of the Fiscal Year Ending March 31, 2025	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The company is in a robust financial situation considering its net cash and margin position.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company benefits from high valuations in earnings multiples.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
NIHON KOHDEN CORPORATION	+6.68%	2.6B	-
THERMO FISHER SCIENTIFIC	+8.38%	220B	B
DANAHER CORPORATION	+15.78%	198B	B-
INTUITIVE SURGICAL, INC.	+23.68%	148B	B-
BOSTON SCIENTIFIC CORPORATION	+31.27%	112B	A-
SIEMENS HEALTHINEERS AG	+4.18%	66.17B	A-
EDWARDS LIFESCIENCES CORPORATION	+14.19%	52.47B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.70%	50.77B	B+
AGILENT TECHNOLOGIES, INC.	-3.93%	38.97B	A
GE HEALTHCARE TECHNOLOGIES INC.	-0.47%	35.13B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes